Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine
(Thomson Reuters ONE) -
GAITHERSBURG, Md., May 11, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX),
today announced that Dr. James F. Cummings has been promoted to Vice President,
Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as
Senior Director of Clinical Development in September 2015, with a specific focus
on advancing Novavax' programs within emerging infectious disease. Previously,
Dr. Cummings served as the Director for Global Emerging Infections Surveillance
and Response System (GEIS) at the Armed Forces Health Surveillance Branch
(AFHSB), Director, Translational Medicine Branch & Division of Regulated
Activities at Walter Reed Army Institute of Research (WRAIR) and Consultant to
the U.S. Army Surgeon General for all Medical Research and Development.
"In his short tenure at the company, James has shown his ability to
constructively organize, motivate and manage complex development programs," said
Stanley C. Erck, President and CEO. "His demonstrated expertise in product
development and leadership capabilities earned James the appointment of Project
Lead for our nanoparticle influenza vaccine candidate development program, and
promotion to Vice President. I am thrilled to congratulate James for his
successes here at Novavax."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases. Its
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir(at)novavax.com
240-268-2000
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Avino Reports Q1 2017 Financial Results
Datum: 11.05.2017 - 14:05 Uhr
Sprache: Deutsch
News-ID 541928
Anzahl Zeichen: 2431
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
